The Public Health Impact of Direct-To-Consumer Advertising of Prescription Drugs
This report explores the public health impact of direct-to-consumer advertising based on a nationally representative sample of adults who discussed advertised drugs with their physicians. The report departed from an existing body of research, which evaluates attitudes and opinions, and instead examined actual healthcare experiences and outcomes. The research found that DTC prompted discussion between patients and their physicians, and prompted additional care by their physicians, including ordering new prescriptions. However, fewer than half of new prescriptions were for the drug that was advertised.
CER Tweets of the Week (June 3-7, 2013)
The Patient-Centered Outcomes Research Institute (PCORI) generated buzz on Twitter this week with the announcement of the winners of the PCORI...Quantifying the Impact of CER: Let Us Avoid the Mistakes of the Past
In his latest "From Methods to Policy" column, published in the January 2013 issue of the Journal of Comparative Effectiveness Research, NPC Chief...
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
PCORI Outlines Efforts to Engage Patients
Dr. Rachael Fleurence, Scientist,Patient-Centered Outcomes Research Institute, outlines the many ways heragency is engaging patients and other...
National Pharmaceutical Council Comments on Patient-Centered Outcomes Research Institute (PCORI) Board of Governors
Washington, DC (September 23, 2010) -- National Pharmaceutical Council (NPC) President Dan Leonard today commented on the appointment of the...NBCH eValue8™ Report Reveals Health Plans’ Ability to Align Employee Incentives to Improve Health
Washington, DC (November 30, 2009) – The current rate of health care cost increases are unsustainable and health care purchasers are increasingly...Avalere Explores Impact of Comparative Effectiveness Research on Healthcare Innovation
Washington, DC (November 17, 2009) – A new Avalere Health report presents an analytic framework for evaluating the impact of comparative...Value-Based Insurance Design: Helping Employers Improve the Value of Health Care
Washington, DC. (August 24, 2009) -- As members of Congress continue to debate proposals for health care reform, the National Pharmaceutical...Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
Medications are more than an item on the balance sheet for health care providers. Pharmaceuticals offer a route to manage costs while achieving...National Pharmaceutical Council Prepared Commentary Before the Patient-Centered Outcomes Research Institute
Thank you for the opportunity to comment. I have enjoyed the opportunity to witness first-hand the progress, careful thought and deliberation, and...CER Done Right: Why It Matters
The health care reform law is aimed at reshaping the health care landscape through the creation of many new regulations and regulatory...PCORI Outlines Efforts to Engage Patients
Dr. Rachael Fleurence, Scientist,Patient-Centered Outcomes Research Institute, outlines the many ways heragency is engaging patients and other...UPenn's Dr. Caplan on Communicating CER to Patients
Univ. of Pennsylvania Director of the Center for Bioethics Dr. Art Caplan outlines an ethical framework for communicating comparative effectiveness...Prioritizing CER: Assessing Public Health & Being Open With the Public
NPC Chief Science Officer Dr. Robert Dubois discusses an optimal decision-making process that could be utilized by research organizations in setting...Health Technology Assessment (1) - Definitions
Dr. Michael Drummond of the University of York and the London School of Economics begins his presentation with a working definition of the term "...CER Tweets of the Week (June 3-7, 2013)
The Patient-Centered Outcomes Research Institute (PCORI) generated buzz on Twitter this week with the announcement of the winners of the PCORI...Quantifying the Impact of CER: Let Us Avoid the Mistakes of the Past
In his latest "From Methods to Policy" column, published in the January 2013 issue of the Journal of Comparative Effectiveness Research, NPC Chief...Webinar: Role of Pharmaceuticals in the ACO Environment
The National Pharmaceutical Council invites you to participate in an Advisor Live webinar, "The role of pharmaceuticals in the accountable care...The Good, the Bad, and the Different: Deciphering Heterogeneity
Heterogeneity is the variation in, or diversity of, participants, interventions, and outcomes within or between studies and patients. Every day,...Research
Growth in Use of Lipid-Lowering Therapies: Are We Targeting the Right Patients?
Within the context of concerns over growing prescrip
- 1 of 30
- >
Commentary & Testimony
Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?
Framework Helps ACOs Leverage Pharmaceuticals to Realize Quality, Cost Goals
National Pharmaceutical Council Prepared Commentary Before the Patient-Centered Outcomes Research Institute
CER Done Right: Why It Matters
Proposed ACO Rules Raising More Questions Than Answers